Back to Orexin a research
orexin a other 2026-04-25 PubMed

Intermittent Fasting Improves Metabolism and Hormones in Obesity

Metabolic and Neuroendocrine Responses to Intermittent Fasting in Obesity.

Background

Obesity is a pervasive global health challenge, strongly linked to severe metabolic disorders such as type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease. Current weight management strategies often face issues with long-term adherence and efficacy, underscoring the critical need for innovative and sustainable interventions. This study specifically addresses the knowledge gap by investigating the comprehensive impact of intermittent fasting on both metabolic markers and neuroendocrine responses in individuals with obesity, aiming to elucidate its physiological mechanisms beyond simple caloric restriction.

Study Design

Population
Individuals with obesity and associated metabolic disorders such as type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease.
Intervention
Intermittent fasting, with specific details on dose, route, and duration not specified in the digest.
Outcome
The comprehensive impact on both metabolic markers and neuroendocrine responses.

orexin a
Source: pubmed:41752655 · Ingested 2026-04-25 · Digest: gemini-2.5-flash